Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Grace Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 9 | 12 | +3 |
| Shares | 50.3K | 410.6K | +360.4K (+717.0%) |
| Value | $24.8K | $189.6K | +$164.8K (+665.6%) |
New holders (5)
Institutions that held Grace Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| TD Private Client Wealth LLC | 240,797 | $110.7K | 0.00% |
| Renaissance Technologies LLC | 90,768 | $42.0K | 0.00% |
| Virtu Financial LLC | 22,254 | $10.0K | 0.00% |
| UBS Group AG | 3,744 | $1.72K | 0.00% |
| JPMorgan Chase & Co | 1,250 | $1.00K | 0.00% |
Sold out (2)
Institutions that held Grace Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Money Concepts Capital Corp | 187 | $94 |
| BlackRock Inc. | 62 | $31 |